A newly identified susceptibility locus near FOXP1 modifies the association of gastroesophageal reflux with Barrett's esophagus

Cancer Epidemiology Biomarkers and Prevention

Volumn 24, Issue 11, 2015, Pages 1739-1747

  Dai, James Y ^a,b   De Dieu Tapsoba, Jean ^a   Buas, Matthew F ^a   Onstad, Lynn E ^a   Levine, David M ^b   Risch, Harvey A ^c   Chow, Wong Ho ^d   Bernstein, Leslie ^e   Ye, Weimin ^f   Lagergren, Jesper ^f,g   Bird, Nigel C ^h   Corley, Douglas A ^i,j   Shaheen, Nicholas J ^k   Wu, Anna H ^l   Reid, Brian J ^a   Hardie, Laura J ^m   Whiteman, David C ⁿ   Vaughan, Thomas L ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c YALE UNIVERSITY   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^f KAROLINSKA INSTITUTE   (Sweden)

^g KING'S COLLEGE LONDON   (United Kingdom)

^h UNIVERSITY OF SHEFFIELD   (United Kingdom)

ⁱ DIVISION OF RESEARCH   (United States)

^j KAISER PERMANENTE   (United States)

^k UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^l UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^m UNIVERSITY OF LEEDS   (United Kingdom)

ⁿ QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXP1; UNCLASSIFIED DRUG; FORKHEAD TRANSCRIPTION FACTOR; FOXP1 PROTEIN, HUMAN; GENETIC MARKER; REPRESSOR PROTEIN;

ADULT; ALLELE; ARTICLE; BARRETT ESOPHAGUS; BODY MASS; CONTROLLED STUDY; DISEASE ASSOCIATION; ESOPHAGEAL ADENOCARCINOMA; GASTROESOPHAGEAL REFLUX; GENE LOCUS; GENETIC SUSCEPTIBILITY; GENOTYPE; GENOTYPE ENVIRONMENT INTERACTION; HEARTBURN; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK FACTOR; SMOKING; ADENOCARCINOMA; CASE CONTROL STUDY; COMPLICATION; ESOPHAGEAL NEOPLASMS; FEMALE; GENETIC MARKER; GENETIC PREDISPOSITION; GENETICS; GENOME-WIDE ASSOCIATION STUDY; HOMOZYGOTE; MALE; PHYSIOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM;

ADENOCARCINOMA; BARRETT ESOPHAGUS; CASE-CONTROL STUDIES; ESOPHAGEAL NEOPLASMS; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GASTROESOPHAGEAL REFLUX; GENETIC LOCI; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HOMOZYGOTE; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; REPRESSOR PROTEINS; RISK FACTORS;

EID: 84946615818     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-15-0507     Document Type: Article

References (52)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: Globocan 2008. Int J Cancer 2010;127:2893-917.
2. Yousef F, Cardwell C, Cantwell MM, Galway K, Johnston BT, Murray L. The incidence of esophageal cancer and high-grade dysplasia in Barrett's esophagus: a systematic review and meta-analysis. Am J Epidemiol 2008;168:237-49.
3. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF Jr. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991;265:1287-9.
4. Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 2005;97:142-6.
5. Brown LM, Devesa SS, Chow WH. Incidence of adenocarcinoma of the esophagus among white americans by sex, stage, and age. J Natl Cancer Inst 2008;100:1184-7.
6. Stavrou EP, McElroy HJ, Baker DF, Smith G, Bishop JF. Adenocarcinoma of the oesophagus: incidence and survival rates in new south wales, 1972-2005. Med J Aust 2009;191:310-4.
7. Reid BJ, Li X, Galiepeau PC, Vaughan TL. Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis. Nat Rev 2010;10:87-101.
8. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1990;340:825-31.
9. Anderson LA, Watson RG, Murphy SJ, Johnston BT, Comber H, Mc Guigan J, et al. Risk factors for Barrett's oesophagus and oesophageal adenocarcinoma: results from the finbar study. World J Gastroenterol 2007;13:1585-94.
10. Engel LS, Chow WH, Vaughan TL, Gammon MD, Risch HA, Stanford JL, et al. Population attributable risks of esophageal and gastric cancers. Cancer Epidemiol Biomarkers Prev 2003;95:1404-13.
11. Steevens J, Schouten LJ, Driessen AL, Huysentruyt CJ, Keulemans YC, Goldbohm RA, et al. A prospective cohort study on overweight, smoking, alcohol consumption, and risk of Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 2011;20:345-58.
12. Olsen CM, Pandeya N, Green AC, Webb PMWhiteman DC for the Australian Cancer Study. Population attributable fractions of adenocarcinoma of the esophagus and gastrophageal junction. Am J Epidemiol 2011;174:582-90.
13. Corley DA, Kubo A, Zhao W. Abdominal obesity and the risk of esophageal and gastric cardia carcinomas. Cancer Epidemiol Biomarkers Prev 2008;17:352-8.
14. Johansson J, Hakansson HO, Mellblom L, Kempas A, Johansson KE, Granath F, et al. Risk factors for Barrett's oesophagus: a population-based approach. Scand J Gastroenterol 2007;42:148-56.
15. Moons LM, Kuipers EJ, Rygiel AM, Groothuismink AZ, Geldof H, Bode WA, et al. COX-2 CA-haplotype is a risk factor for the development of esophageal adenocarcinoma. Am J Gastroenterol 2007;102:2373-9.
16. Kristinsson JO, Van Westerveld P, Te Morsche RH, Roelofs HM, Wobbes T, Witteman BJ, et al. Cyclooxygenase-2 polymorphisms and the risk of esophageal adeno-or squamous cell carcinoma. World J Gastroenterol 2009;15:3493-7.
17. Babar M, Ryan AW, Anderson LA, Segurado R, Turner G, Murray LJ, et al. Genes of the interleukin-18 pathway are associated with susceptibility to Barrett's esophagus and esophageal adenocarcinoma. Am J Gastroenterol 2012;107:1331-41.
18. Menke V, Van Zoest KP, Moons LM, Hansen B, Pot RG, Siersema PD, et al. NcoI TNF-b gene polymorphism and TNF expression are associated with an increased risk of developing Barrett's esophagus and esophageal adenocarcinoma. Scand J Gastroenterol 2012;47:378-86.
19. Casson AG, Zheng Z, Porter GA, Guernsey DL. Genetic polymorphisms of microsomal epoxide hydroxylase and glutathione Stransferases M1, T1 and P1, interactions with smoking, and risk for esophageal (Barrett) adenocarcinoma. Cancer Detect Prev 2006;30:423-31.
20. Bull LM, White DL, Bray M, Nurgalieva Z, El-Serag HB. Phase I and II enzyme polymorphisms as risk factors for Barrett's esophagus and esophageal adenocarcinoma: a systematic review and meta-analysis. Dis Esophagus 2009;22:571-87.
21. Doecke J, Zhao ZZ, Pandeya N, Sadeghi S, Stark M, Green AC, et al. Polymorphisms in MGMT and DNA repair genes and the risk of esophageal adenocarcinoma. Int J Cancer 2008;123:174-80.
22. Su Z, Gay LJ, Strange A, Palles C, Band G, Whiteman DC, et al. Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett's esophagus. Nat Genet 2012;44:1131-6.
23. Palles C, Chegwidden L, Li X, Findlay JM, Farnham G, Castro Giner F, et al. Polymorphisms near TBX5 and GDF7 are associated with increased risk for Barrett's esophagus. Gastroenterology 2015;148:367-78.
24. Levine DM, Ek WE, Zhang R, Liu X, Onstad L, Sather C, et al. A genome-wide association study identifies new susceptibility loci for esophageal adenocarcinoma and Barrett's esophagus. Nat Genet 2013;45:1487-93.
25. Ek WE, Levine DM, D'Amato M, Pedersen NL, Magnusson PK, Bresso F, et al. Germline genetic contributions to risk for esophageal adenocarcinoma, Barrett's esophagus and gastroesophageal reflux. JNCI 2013;105:1711-8.
26. Di Martino E, Hardie LJ, Wild CP, Gong YY, Olliver JR, Gough MS, et al. The NAD (P) H:quinone oxidoreductase I C609T polymorphism modifies the risk of Barrett esophagus and esophageal adenocarcinoma. Genet Med 2007;9:341-7.
27. Zhai R, Liu G, Asomaning K, Su L, Kulke MH, Heist RS, et al. Genetic polymorphisms of VEGF, interactions with cigarette smoking exposure and esophageal adenocarcinoma risk. Carcinogenesis 2008;29:2330-4.
28. Cheung WY, Zhai R, Bradbury P, Hopkins J, Kulke MH, Heist RS, et al. Single nucleotide polymorphisms in the matrix metalloproteinase gene family and the frequency and duration of gastroesophageal reflux disease influence the risk of esophageal adenocarcinoma. Int J Cancer 2012;131:2478-86.
29. Zhai R, Chen F, Liu G, Su L, Kulke MH, Asomaning K, et al. Interactions among genetic variants in apoptosis pathway genes, reflux symptoms, body mass index, and smoking indicate two distinct etiologic patterns of esophageal adenocarcinoma. J Clin Oncol 2010;28:2445-51.
30. Wu IC, Zhao Y, Zhai R, Liu CY, Chen F, Ter-Minassian M, et al. Interactions between genetic polymorphisms in the apoptotic pathway and environmental factors on esophageal adenocarcinoma risk. Carcinogenesis 2011;32:502-6.
31. Zhai R, Zhao Y, Liu G, Ter-Minassian M, Wu IC, Wang Z, et al. Interactions between environmental factors and polymorphisms in angiogenesis pathway genes in esophageal adenocarcinoma risk: a case-only study. Cancer 2012;118:804-11.
32. Prentice RL, Huang Y, Hinds DA, Peters U, Cox DR, Beilharz E, et al. Variation in the FGFR2 gene and the effect of a low-fat dietary pattern on invasive breast cancer. Cancer Epidemiol Biomarker Prev 2010;19:74-9.
33. Kooperberg C, LeBlanc M. Increasing the power of identifying gene X gene interactions in genome-wide association studies. Genet Epidemiol 2008;32:255-63.
34. Dai JY, Kooperberg C, LeBlanc M, Prentice RL. Two-stage testing procedures with independent filtering for genome-wide gene-environment interaction. Biometrika 2012;99:929-44.
35. Laurie CC, Doheny KF, Mirel DB, Pugh EW, Bierut LJ, Bhangale T, et al. Quality control and quality assurance in genotypic data for genome-wide association studies. Genet Epidemiol 2010;34:591-602.
36. Cook MB, Corley DA, Murray LJ, Liao LM, Kamangar F, Ye W, et al. Gastroesophageal reflux in relation to adenocarcinomas of the esophagus: a pooled analysis from the Barrett's and esophageal adenocarcinoma consortium (BEACON). PLoS ONE 2014;9:e103508.
37. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. JRStat Soc B 1995;57:289-300.
38. 1000 Genomes Project. An integrated map of genetic variation from 1, 092 human genomes. Nature 2012;135:0-9.
39. Bernstein BE, Stamatoyannopoulos JA, Costello JF, Ren B, Milosavljevic A, Meissner A, et al. The NIH roadmap epigenomics mapping consortium. Nat Biotechnol 2010;28:1045-8.
40. Ward LD, Kellis M. HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. Nucleic Acids Res 2012;40(Database issue):D930-4.
41. Rosenbloom KR, Sloan CA, Malladi VS, Dreszer TR, Learned K, Kirkup VM, et al. ENCODE data in the UCSC Genome Browser: year 5 update. Nucleic Acids Res 2013;41(Database issue):D56-63.
42. The GTEx Consortium. The genotype-tissue expression (GTEx) pilot analysis: multitissue gene regulation in humans. Science 2015;348:648-60.
43. Lam EW, Brosens JJ, Gomes AR, Koo CY. Forkhead box proteins: tuning forks for transcriptional harmony. Nat Rev Cancer 2013;13:482-95.
44. Hannenhalli S, Kaestner KH. The evolution of Fox genes and their role in development and disease. Nat Rev Genet 2009;10:233-40.
45. Myatt SS, Lam EW. The emerging roles of forkhead box (Fox) proteins in cancer. Nat Rev Cancer 2007;7:847-59.
46. Shu W, Lu MM, Zhang Y, Tucker PW, Zhou D, Morrisey EE. Foxp2 and Foxp1 cooperatively regulate lung and esophagus development. Development 2007;134:1991-2000.
47. Banham AH, Beasley N, Campo E, Fernandez PL, Fidler C, Gatter K, et al. The FOXP1 winged helix transcription factor is a novel candidate tumor suppressor gene on chromosome 3p. Cancer Res 2001;61:8820-9.
48. Fox SB, Brown P, Han C, Ashe S, Leek RD, Harris AL, et al. Expression of the forkhead transcription factor FOXP1 is associated with estrogen receptor alpha and improved survival in primary human breast carcinomas. Clin Cancer Res 2004;10:3521-7.
49. Banham AH, Connors JM, Brown PJ, Cordell JL, Ott G, Sreenivasan G, et al. Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma. Clin Cancer Res 2005;11:1065-72.
50. Koon HB, Ippolito GC, Banham AH, Tucker PW. FOXP1: a potential therapeutic target in cancer. Expert Opin Ther Targets 2007;11:955-65.
51. Hoyo C, Cook NB, Kamangar F, Freedman ND, Whiteman DC, Bernstein L, et al. Body mass index in relation to oesophageal and oesophagogastric junction adenocarcinomas: a pooled analysis from the International BEACON Consortium. Int J Epidemiol 2012;41:1706-18.
52. Cook MB, Kamangar F, Whiteman DC, Freedman ND, Gammon MD, Bernstein L, et al. Cigarette smoking and adenocarcinomas of the esophagus and esophagogastric junction: a pooled analysis from the international BEACON consortium. J Natl Cancer Inst 2010;102:1344-53